Literature DB >> 20951261

Spliced stromal cell-derived factor-1α analog stimulates endothelial progenitor cell migration and improves cardiac function in a dose-dependent manner after myocardial infarction.

William Hiesinger1, John R Frederick, Pavan Atluri, Ryan C McCormick, Nicole Marotta, Jeffrey R Muenzer, Y Joseph Woo.   

Abstract

OBJECTIVES: Stromal cell-derived factor (SDF)-1α is a potent endogenous endothelial progenitor cell (EPC) chemokine and key angiogenic precursor. Recombinant SDF-1α has been demonstrated to improve neovasculogenesis and cardiac function after myocardial infarction (MI) but SDF-1α is a bulky protein with a short half-life. Small peptide analogs might provide translational advantages, including ease of synthesis, low manufacturing costs, and the potential to control delivery within tissues using engineered biomaterials. We hypothesized that a minimized peptide analog of SDF-1α, designed by splicing the N-terminus (activation and binding) and C-terminus (extracellular stabilization) with a truncated amino acid linker, would induce EPC migration and preserve ventricular function after MI.
METHODS: EPC migration was first determined in vitro using a Boyden chamber assay. For in vivo analysis, male rats (n = 48) underwent left anterior descending coronary artery ligation. At infarction, the rats were randomized into 4 groups and received peri-infarct intramyocardial injections of saline, 3 μg/kg of SDF-1α, 3 μg/kg of spliced SDF analog, or 6 μg/kg spliced SDF analog. After 4 weeks, the rats underwent closed chest pressure volume conductance catheter analysis.
RESULTS: EPCs showed significantly increased migration when placed in both a recombinant SDF-1α and spliced SDF analog gradient. The rats treated with spliced SDF analog at MI demonstrated a significant dose-dependent improvement in end-diastolic pressure, stroke volume, ejection fraction, cardiac output, and stroke work compared with the control rats.
CONCLUSIONS: A spliced peptide analog of SDF-1α containing both the N- and C- termini of the native protein induced EPC migration, improved ventricular function after acute MI, and provided translational advantages compared with recombinant human SDF-1α.
Copyright © 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951261      PMCID: PMC4135713          DOI: 10.1016/j.jtcvs.2010.08.012

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  28 in total

1.  Attachment of C-terminus of SDF-1 enhances the biological activity of its N-terminal peptide.

Authors:  J Luo; Z Luo; N Zhou; J W Hall; Z Huang
Journal:  Biochem Biophys Res Commun       Date:  1999-10-14       Impact factor: 3.575

2.  Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy.

Authors:  Pavan Atluri; George P Liao; Corinna M Panlilio; Vivian M Hsu; Matthew J Leskowitz; Kevin J Morine; Jeffrey E Cohen; Mark F Berry; Erik E Suarez; Danielle A Murphy; William M F Lee; Timothy J Gardner; H Lee Sweeney; Y Joseph Woo
Journal:  Ann Thorac Surg       Date:  2006-05       Impact factor: 4.330

3.  Effects of off-pump versus on-pump coronary artery bypass grafting on function and viability of circulating endothelial progenitor cells.

Authors:  Marc Ruel; Erik J Suuronen; Jianming Song; Varun Kapila; Derek Gunning; Geeta Waghray; Fraser D Rubens; Thierry G Mesana
Journal:  J Thorac Cardiovasc Surg       Date:  2005-09       Impact factor: 5.209

4.  Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty.

Authors:  Giuseppe Tarantini; Renato Razzolini; Luisa Cacciavillani; Claudio Bilato; Cristiano Sarais; Francesco Corbetti; Martina Perazzolo Marra; Massimo Napodano; Angelo Ramondo; Sabino Iliceto
Journal:  Am J Cardiol       Date:  2006-08-28       Impact factor: 2.778

5.  Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure.

Authors:  Y Joseph Woo; Corinna M Panlilio; Richard K Cheng; George P Liao; Pavan Atluri; Vivian M Hsu; Jeffrey E Cohen; Hina W Chaudhry
Journal:  Circulation       Date:  2006-07-04       Impact factor: 29.690

6.  Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction.

Authors:  C E Rochitte; J A Lima; D A Bluemke; S B Reeder; E R McVeigh; T Furuta; L C Becker; J A Melin
Journal:  Circulation       Date:  1998-09-08       Impact factor: 29.690

7.  Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2.

Authors:  Y Joseph Woo; Corinna M Panlilio; Richard K Cheng; George P Liao; Erik E Suarez; Pavan Atluri; Hina W Chaudhry
Journal:  J Thorac Cardiovasc Surg       Date:  2007-02-22       Impact factor: 5.209

8.  Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury.

Authors:  J Dawn Abbott; Yan Huang; Dingang Liu; Reed Hickey; Diane S Krause; Frank J Giordano
Journal:  Circulation       Date:  2004-11-08       Impact factor: 29.690

9.  Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy.

Authors:  Y Joseph Woo; Todd J Grand; Mark F Berry; Pavan Atluri; Mireille A Moise; Vivian M Hsu; Jeffrey Cohen; Omar Fisher; Jeffrey Burdick; Matthew Taylor; Suzanne Zentko; George Liao; Max Smith; Steve Kolakowski; Vasant Jayasankar; Timothy J Gardner; H Lee Sweeney
Journal:  J Thorac Cardiovasc Surg       Date:  2005-08       Impact factor: 5.209

10.  Improvement of contractility accompanies angiogenesis rather than arteriogenesis in chronic myocardial ischemia.

Authors:  Claudia Heilmann; Caterina Kostic; Bodo Giannone; Andrea Busse Grawitz; Werner Armbruster; Georg Lutter; Friedhelm Beyersdorf; Heike Göbel
Journal:  Vascul Pharmacol       Date:  2006-03-09       Impact factor: 5.773

View more
  13 in total

1.  Biochemically engineered stromal cell-derived factor 1-alpha analog increases perfusion in the ischemic hind limb.

Authors:  Bryan B Edwards; Alexander S Fairman; Jeffrey E Cohen; John W MacArthur; Andrew B Goldstone; Jeffrey B Woo; William Hiesinger; Y Joseph Woo
Journal:  J Vasc Surg       Date:  2015-09-12       Impact factor: 4.268

Review 2.  Stem cell sources for vascular tissue engineering and regeneration.

Authors:  Vivek K Bajpai; Stelios T Andreadis
Journal:  Tissue Eng Part B Rev       Date:  2012-07-03       Impact factor: 6.389

3.  Myocardial tissue elastic properties determined by atomic force microscopy after stromal cell-derived factor 1α angiogenic therapy for acute myocardial infarction in a murine model.

Authors:  William Hiesinger; Matthew J Brukman; Ryan C McCormick; J Raymond Fitzpatrick; John R Frederick; Elaine C Yang; Jeffrey R Muenzer; Nicole A Marotta; Mark F Berry; Pavan Atluri; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2012-01-20       Impact factor: 5.209

Review 4.  Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment.

Authors:  Guoyou Huang; Fei Li; Xin Zhao; Yufei Ma; Yuhui Li; Min Lin; Guorui Jin; Tian Jian Lu; Guy M Genin; Feng Xu
Journal:  Chem Rev       Date:  2017-10-09       Impact factor: 60.622

5.  Bioengineered stromal cell-derived factor-1α analogue delivered as an angiogenic therapy significantly restores viscoelastic material properties of infarcted cardiac muscle.

Authors:  Alen Trubelja; John W MacArthur; Joseph J Sarver; Jeffrey E Cohen; George Hung; Yasuhiro Shudo; Alexander S Fairman; Jay Patel; Bryan B Edwards; Scott M Damrauer; William Hiesinger; Pavan Atluri; Y Joseph Woo
Journal:  J Biomech Eng       Date:  2014-08       Impact factor: 2.097

6.  Oxygen-dependent quenching of phosphorescence used to characterize improved myocardial oxygenation resulting from vasculogenic cytokine therapy.

Authors:  William Hiesinger; Sergei A Vinogradov; Pavan Atluri; J Raymond Fitzpatrick; John R Frederick; Rebecca D Levit; Ryan C McCormick; Jeffrey R Muenzer; Elaine C Yang; Nicole A Marotta; John W MacArthur; David F Wilson; Y Joseph Woo
Journal:  J Appl Physiol (1985)       Date:  2011-02-03

7.  Mathematically engineered stromal cell-derived factor-1α stem cell cytokine analog enhances mechanical properties of infarcted myocardium.

Authors:  John W MacArthur; Alen Trubelja; Yasuhiro Shudo; Philip Hsiao; Alexander S Fairman; Elaine Yang; William Hiesinger; Joseph J Sarver; Pavan Atluri; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2013-01       Impact factor: 5.209

8.  Preclinical evaluation of the engineered stem cell chemokine stromal cell-derived factor 1α analog in a translational ovine myocardial infarction model.

Authors:  John W Macarthur; Jeffrey E Cohen; Jeremy R McGarvey; Yasuhiro Shudo; Jay B Patel; Alen Trubelja; Alexander S Fairman; Bryan B Edwards; George Hung; William Hiesinger; Andrew B Goldstone; Pavan Atluri; Robert L Wilensky; James J Pilla; Joseph H Gorman; Robert C Gorman; Y Joseph Woo
Journal:  Circ Res       Date:  2013-12-23       Impact factor: 17.367

9.  The development and characterization of SDF1α-elastin-like-peptide nanoparticles for wound healing.

Authors:  Agnes Yeboah; Rick I Cohen; Renea Faulknor; Rene Schloss; Martin L Yarmush; Francois Berthiaume
Journal:  J Control Release       Date:  2016-04-16       Impact factor: 9.776

10.  Sustained release of engineered stromal cell-derived factor 1-α from injectable hydrogels effectively recruits endothelial progenitor cells and preserves ventricular function after myocardial infarction.

Authors:  John W MacArthur; Brendan P Purcell; Yasuhiro Shudo; Jeffrey E Cohen; Alex Fairman; Alen Trubelja; Jay Patel; Philip Hsiao; Elaine Yang; Kelsey Lloyd; William Hiesinger; Pavan Atluri; Jason A Burdick; Y Joseph Woo
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.